Edition:
United Kingdom

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

51.67USD
15 Feb 2019
Change (% chg)

$0.84 (+1.65%)
Prev Close
$50.83
Open
$51.42
Day's High
$51.87
Day's Low
$50.93
Volume
3,307,877
Avg. Vol
3,162,490
52-wk High
$70.04
52-wk Low
$44.30

Latest Key Developments (Source: Significant Developments)

EU Medicines Agency Recommends Approval Of Pfizer's Vizimpro, Bristol-Myers' Reyataz
Friday, 1 Feb 2019 

Feb 1 (Reuters) - EMA's CHMP::EU MEDICINES AGENCY RECOMMENDATIONS FOR JAN 2019.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF PFIZER’S LUNG CANCER DRUG VIZIMPRO.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF BRISTOL-MYERS SQUIBB’S HIV DRUG REYATAZ.  Full Article

Celgene Q4 Earnings Per Share $1.50
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Celgene Corp ::CELGENE REPORTS FOURTH QUARTER AND FULL YEAR 2018 OPERATING AND FINANCIAL RESULTS.Q4 REVENUE $4.037 BILLION VERSUS REFINITIV IBES ESTIMATE OF $3.99 BILLION.Q4 EARNINGS PER SHARE $1.50.Q4 EARNINGS PER SHARE ESTIMATE $2.32 -- REFINITIV IBES DATA.REAFFIRMING 2020 FINANCIAL OUTLOOK.REVLIMID SALES FOR Q4 INCREASED 16 PERCENT TO $2,549 MILLION.OZANIMOD U.S. AND EU REGULATORY SUBMISSIONS ON-TRACK FOR Q1 2019.OTEZLA SALES IN Q4 WERE $448 MILLION, A 21 PERCENT INCREASE YEAR-OVER-YEAR.QTRLY ADJUSTED EARNINGS PER SHARE $2.39.BRISTOL-MYERS SQUIBB AND CELGENE EXPECT TO CLOSE TRANSACTION IN Q3 OF 2019.SEES 2019 GAAP DILUTED EPS $8.40 TO $9.08.2019 GUIDANCE FOR TOTAL REVENUE AND NET PRODUCT SALES OF REVLIMID & OTEZLA UNCHANGED FROM GUIDANCE PROVIDED ON JAN. 7.FY2019 EARNINGS PER SHARE VIEW $10.42, REVENUE VIEW $17.00 BILLION -- REFINITIV IBES DATA.  Full Article

Bristol-Myers Says After Celgene Deal Sees More Than $50 Bln In 2025 Revenue
Thursday, 24 Jan 2019 

Jan 24 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL MYERS SAYS AFTER CELGENE DEAL SEES MORE THAN $50 BILLION IN 2025 REVENUE , MORE THAN $20 BILLION IN 2025 EARNINGS-SLIDE.  Full Article

European Commission Approves Opdivo Plus Low-Dose Yervoy For Treatment Of Patients With Form Of Advanced Renal Cell Carcinoma
Monday, 14 Jan 2019 

Jan 14 (Reuters) - Bristol-Myers Squibb Co ::EUROPEAN COMMISSION APPROVES OPDIVO (NIVOLUMAB) PLUS LOW-DOSE YERVOY (IPILIMUMAB) FOR FIRST-LINE TREATMENT OF PATIENTS WITH INTERMEDIATE- AND POOR-RISK ADVANCED RENAL CELL CARCINOMA.BRISTOL-MYERS SQUIBB CO - APPROVAL BASED ON RESULTS FROM PHASE 3 CHECKMATE -214 TRIAL.  Full Article

Celgene CEO Mark Alles Says Drug Pricing Is Coming Down Year-On-Year On A Net Basis - CNBC Interview
Monday, 7 Jan 2019 

Jan 7 (Reuters) - :CELGENE CEO MARK ALLES SAYS DRUG PRICING IS COMING DOWN YEAR-ON-YEAR ON A NET BASIS - CNBC INTERVIEW.CELGENE CEO ALLES SAYS FOURTH QUARTER WOULD BE A RECORD QUARTER FOR COMPANY.  Full Article

Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For Planned Phase 3 Trial To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Bristol-Myers Squibb Co ::MIRATI ANNOUNCES CLINICAL COLLABORATION WITH BRISTOL-MYERS SQUIBB FOR THE PLANNED PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER TO EVALUATE SITRAVATINIB IN COMBINATION WITH NIVOLUMAB (OPDIVO®).MIRATI THERAPEUTICS INC - PHASE 3 PIVOTAL TRIAL IS EXPECTED TO START IN FIRST HALF OF 2019.MIRATI THERAPEUTICS INC - UNDER TERMS OF COLLABORATION, MIRATI WILL SPONSOR AND FUND CLINICAL TRIAL.MIRATI THERAPEUTICS INC - UNDER TERMS OF COLLABORATION BRISTOL-MYERS SQUIBB WILL PROVIDE NIVOLUMAB AT NO COST.  Full Article

Bristol-Myers Squibb's Sprycel Now Approved In Combination With Chemotherapy In Certain Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Wednesday, 2 Jan 2019 

Jan 2 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB’S SPRYCEL® (DASATINIB) TABLETS NOW APPROVED IN COMBINATION WITH CHEMOTHERAPY IN CERTAIN PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA.BRISTOL-MYERS SQUIBB CO - APPROVAL WAS GRANTED FOLLOWING PRIORITY REVIEW BY FDA, IS BASED ON DATA FROM PHASE 2 STUDY, CA180-372.  Full Article

X-Chem Enters Strategic Collaboration With Bristol-Myers Squibb
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - X-Chem Inc::X-CHEM ENTERS STRATEGIC COLLABORATION WITH BRISTOL-MYERS SQUIBB.X-CHEM - WILL RECEIVE UP-FRONT TECHNOLOGY ACCESS AND RESEARCH PAYMENTS.X-CHEM INC - ANNOUNCED SIGNING OF A BROAD STRATEGIC DRUG DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB.X-CHEM - CO IS ENTITLED TO POTENTIAL PAYMENTS UPON ACHIEVEMENT OF PRE-CLINICAL, DEVELOPMENT, AND REGULATORY MILESTONES.X-CHEM- BRISTOL-MYERS SQUIBB RECEIVES AN OPTION TO LICENSE COMPOUNDS IDENTIFIED DURING FIRST STAGE OF THIS COLLABORATION.X-CHEM - CO ENTITLED TO ROYALTIES BASED ON SALES OF PRODUCTS RESULTING FROM USE OF TECHNOLOGY.X-CHEM - COLLABORATION WITH BRISTOL-MYERS SQUIBB WILL ENABLE DISCOVERY OF NOVEL LEAD COMPOUNDS FOR COMPLEX DRUG TARGETS OF INTEREST TO BRISTOL-MYERS.  Full Article

Taisho Is Said To Near $1.6 Bln Deal For Bristol-Myers's Upsa Unit - Bloomberg
Monday, 17 Dec 2018 

Dec 16 (Reuters) - :TAISHO IS SAID TO NEAR $1.6 BILLION DEAL FOR BRISTOL-MYERS'S UPSA UNIT - BLOOMBERG, CITING SOURCES.  Full Article

Bristol-Myers Squibb And Vedanta Biosciences Announce New Clinical Collaboration To Evaluate Opdivo,VE800 In Patients With Advanced Or Metastatic Cancers
Monday, 10 Dec 2018 

Dec 10 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB AND VEDANTA BIOSCIENCES ANNOUNCE A NEW CLINICAL COLLABORATION TO EVALUATE OPDIVO (NIVOLUMAB) AND VE800 IN PATIENTS WITH ADVANCED OR METASTATIC CANCERS.  Full Article

Merck, Pfizer drug combo extends kidney cancer survival -study

Feb 16 A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.